The Effect of Suramin on Laboratory Tests of Coagulation

Summary

The antitrypanosomal drug suramin, which has recently been under investigation as a cancer chemotherapeutic agent, has previously been found to induce heparin-like anticoagulants in treated patients. In the currently reported work suramin is shown to have an additional anticoagulant activity that is due to direct effects of the drug on procoagulant proteins. The studies were conducted with pooled normal plasma treated in vitro with suramin and with plasma samples obtained from patients who had received the drug intravenously for 2 weeks. It is demonstrated that in plasma suramin inhibits factors V, VIII, IX, X, XI, and XII, while thrombin, prothrombin, and factor VII are unaffected. The inhibition of factor V is virtually irreversible, although the effect of suramin on the other factors is readily reversed by dilution.

• References

• 1 La Rocca RV, Stein CA, Myers CE. Suramin: prototype of a new generation of antitumor compounds. Cancer Cells 1990; 2: 106-115
• 2 Home MK, Stein CA, La Rocca RV, Myers CE. Circulating glycosaminoglycan anticoagulants associated with suramin treatment. Blood 1988; 71: 273-279
• 3 Klecker RW, Collins JM. Quantification of suramin by reverse-phase ion-pairing high-performance liquid chromatography. J Liquid Chromat 1985; 8: 1685-1696
• 4 Blumenkrantz N, Asboe-Hansen G. New method for quantitative determination of uronic acid. Anal Biochem 1973; 54: 484-489
• 5 von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestim-mung des Fibrinogens. Acta Haematol 1957; 17: 237-246
• 6 Triplett DA, Harms CS. Factor II, V, VII, or X assay. In: Procedures for the Coagulation Laboratory. Educational Products Division, American Society of Clinical Pathologists; Chicago, IL: 1981. pp 34-60
• 7 Ellison N, Ominsky AJ, Wollman H. Is protamine a clinically important anticoagulant?. Anesthesiology 1971; 35: 621-629
• 8 Eisen V, Loveday C. Effects of suramin on complement, blood clotting, fibrinolysis and kinin formation. Br J Pharmacol 1973; 49: 678-687
• 9 Muller WE, Wollert U. Spectroscopic studies on the complex formation of suramin with bovine and human serum albumin. Biochim Biophys Acta 1976; 427: 465-480
• 10 Collins JM, Klecker RW, Yarchoan R, Lane HC, Fauci AS, Redfield RR, Broder S, Myers CE. Clinical pharmacokinetics of suramin in patients with HTLV-III/LVA infection. J Clin Pharmacol 1986; 26: 22-26
• 11 Vansterkenburg ELM, Wilting J, Janssen LHM. Influence of pH on the binding of suramin to human serum albumin. Biochem Pharmacol 1989; 38: 3029-3035
• 12 Town BW, Wills ED, Wilson EJ, Wormall A. Studies on suramin. 8. The action of the drug on enzymes and some other proteins. General considerations. Biochem J 1950; 47: 149-170
• 13 Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem 1988; 57: 915-956